A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies

UCI-17-47
NCT03397706
Cancer - Lymphoid Leukemia
Elizabeth A Brem
Open
Treatment
VRx3996, Valganciclovir
Ib/II
Both
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.